Literature DB >> 18419470

Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

Irja Davidkin1, Sari Jokinen, Mia Broman, Pauli Leinikki, Heikki Peltola.   

Abstract

BACKGROUND: The persistence of antibodies against measles, mumps, and rubella induced by the measles-mumps-rubella (MMR) vaccine and the kinetics of antibody decline after the second MMR vaccine dose were studied in the same cohort for 20 years.
METHODS: Measles, mumps, and rubella antibodies were measured by enzyme immunoassay in 20-year follow-up serum samples (n= 183) of twice-vaccinated individuals, and measles antibodies were also measured in oral fluids (n = 177). Antibody decay was determined in a group (n = 58) with subsequent samples collected 1, 8, and 15 years after the second MMR dose.
RESULTS: In total, 95%, 74%, and 100% of 183 vaccinees were still seropositive for measles, mumps, and rubella, respectively, and 85% of 177 vaccinees had measurable measles antibodies in their oral fluids. The antibody levels declined significantly after the second dose, but subsequently the rate of decline was slower.
CONCLUSIONS: A high rate of seropositivity was found 20 years after the first MMR dose, particularly for rubella and measles. Our results show that MMR vaccine-induced antibodies wane significantly after the second dose. According to epidemiological data, the protection induced by MMR vaccination in Finland seems to persist at least until early adulthood. However, the situation requires constant vigilance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419470     DOI: 10.1086/528993

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  91 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

3.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

4.  Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Authors:  Vijay G Bhoj; Dimitrios Arhontoulis; Gerald Wertheim; James Capobianchi; Colleen A Callahan; Christoph T Ellebrecht; Amrom E Obstfeld; Simon F Lacey; Jan J Melenhorst; Farzana Nazimuddin; Wei-Ting Hwang; Shannon L Maude; Mariusz A Wasik; Adam Bagg; Stephen Schuster; Michael D Feldman; David L Porter; Stephen A Grupp; Carl H June; Michael C Milone
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

Review 5.  [Vaccination in adults].

Authors:  D M Kieninger-Baum; F Zepp
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

6.  Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.

Authors:  P Plans; F de Ory; M Campins; E Álvarez; T Payà; E Guisasola; C Compte; K Vellbé; C Sánchez; M J Lozano; I Aran; A Bonmatí; R Carreras; M Jané; L Cabero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 3.267

7.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

8.  Seropositivity rates for measles, mumps, and rubella IgG and costs associated with testing and revaccination.

Authors:  Brian H Shirts; Ryan J Welch; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

9.  Epidemiology and the economic assessment of a mumps outbreak in a highly vaccinated population, Orange County, New York, 2009-2010.

Authors:  Preeta Krishnan Kutty; Jacqueline Lawler; Elizabeth Rausch-Phung; Ismael R Ortega-Sanchez; Stephen Goodell; Cynthia Schulte; Lynn Pollock; Barbara Valure; Jean Hudson; Kathleen Gallagher; Debra Blog
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

10.  Reduced immunity to measles in adults with major depressive disorder.

Authors:  Bart N Ford; Robert H Yolken; Faith B Dickerson; T Kent Teague; Michael R Irwin; Martin P Paulus; Jonathan Savitz
Journal:  Psychol Med       Date:  2018-03-19       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.